Development and optimisation of downstream processing for next generation biotherapeutics

下一代生物治疗药物下游加工的开发和优化

• 批准号: 102501
• 金额: $ 124.33万
• 依托单位: PURIDIFY LTD.
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2016
• 资助国家: 英国
• 起止时间: 2016 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=102501
• 关键词: Development; optimisation; downstream; processing; next

Global demand for cheaper biotherapeutics drives the need for a reduction in manufacturing costs. Rapid advances in recombinant production technologies are offering new therapeutic possibilities in the treatment of illnesses such as haemophilia, Parkinson’s, and cancer. However, purification of these next generation protein therapeutics is extremely challenging due to the complex macromolecular nature of these structures. New purification processes are needed for these novel products to improve manufacturing efficiencies and economics. This is primarily a result of current chromatographic purification technologies being unable to effectively capture these large bioproducts, such as gene therapy vectors, which are much larger than current therapeutics. This project aims to build on existing collaborations and feasibility data to develop and commercialise an innovative bioprocessing technology to enable the cost effective manufacture of a next generation biotherapeutic.

全球对更便宜的生物疗法的需求推动了降低制造成本的需求。重组生产技术的快速发展为血友病、帕金森氏症和癌症等疾病的治疗提供了新的治疗可能性。然而，由于这些结构的复杂的大分子性质，这些下一代蛋白质疗法的纯化是极其具有挑战性的。这些新产品需要新的提纯工艺来提高生产效率和经济性。这主要是因为目前的层析纯化技术不能有效地捕获这些大的生物产品，如基因治疗载体，这些产品比目前的治疗方法大得多。该项目旨在建立在现有合作和可行性数据的基础上，开发创新的生物处理技术并将其商业化，以实现下一代生物治疗药物的成本效益制造。